China Biobetter EPO Deal Seen Boosting Genexine’s Prospects
This article was originally published in PharmAsia News
Following deals last year in China and ASEAN, Genexine has now inked a $44.5m agreement with a subsidiary of Shanghai Fosun Pharmaceutical to license out a novel long-acting EPO for anemia. The deal is set to further buoy the South Korean bioventure’s global presence and beef up the Chinese firm’s pipeline.
Register for our free email digests: